St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
Biologics
- Amylase or maltose to treat or prevent neurodegeneration (SJ-20-0009)
- Anti-GD2-BB-zeta chimeric receptor (SJ-13-0035)
- Antibodies to Tim4 for use as an immune enhancer and cancer therapeutic (SJ-18-0006)
- Association of neuraminidase regulated exocytosis with cancer metastasis (SJ-11-0012)
- B7-H3-CAR 41BB ligand co-stimulation for solid tumors (SJ-19-0014)
- BCRP/ABCG2 as Stem Cell Marker (SJ-97-0016)
- CD123 CARs with a CD20 safety switch for treatment of AML (SJ-19-0025)
- CD33 CAR (SJ-17-0010)
- CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
- Chimeric IL13-MyD88 and PDL1-MyD88 receptors (SJ-20-0032)
- Chimeric gene and protein generated Optogranules: Light induced stress granules (SJ-18-0010)
- Combination DNMT3a KO and IL10 signaling (SJ-21-0018)
- DNA methylation profile and biomarkers to identify functional T-cells (SJ-17-0002)
- DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)
- Development and optimization of a serotype-independent method of adeno-associated virus (AAV) harvest and purification (SJ-16-0036)
- Differentiating T-cells (SJ-18-0019)
- Erythroid Specific Promoter for Hematopoietic Disorders (SJ-16-0040)
- Ets1 and Rbpj Knock-Outs to Improve T Cell Function (SJ-24-0015)
- Extradomain-B fibronectin (EDB)-targeted CAR immune cell therapy (SJ-19-0029)
- Fibcd1 to treat or prevent muscle wasting (SJ-20-0008)
- GMCSF.IL18 chimeric cytokine receptor for solid tumors (SJ-19-0028)
- GRP78 and CD123 targeted adoptive cell therapy for cancer (SJ-22-0021)
- GRP78 targeted adoptive cell therapy for surface GRP78+ (pediatrics and adult) cancer (SJ-19-0050)
- Gene Responsible for Social Memory in Schizophrenia (SJ-19-0048)
- Gene Therapy Vector Insulator Elements (SJ-20-0026)
- Gene Therapy for Wiskott-Aldrich Syndrome (SJ-19-0012)
- Generation of therapeutic T cell receptors for fibrolamellar cancer (SJ-19-0046)
- HMGA2 in gene therapy vectors (SJ-16-0014)
- Hybrid compounds to treat gastrointestinal infections (SJ-14-0019/UTA 14-01)
- IL13 promoter to express therapeutic genes (SJ-18-0042)
- IL35 receptor (SJ-08-0039)
- Immune cells with DNMT3A gene modifications (SJ-16-0009)
- Immunotherapy with Glutamine to Treat Cancer (SJ-23-0010)
- Improved GD2 Ab for neuroblastoma (SJ-17-0017)
- Improvement producing proteins to treat lysosomal storage disorders (SJ-01-0020)
- Improving HSC engraftment by inhibiting GASP genes (SJ-16-0029)
- Inhibiting ASXL1 to improve T cell Immunotherapy (SJ-22-0034)
- Inhibiting Mir-451 to treat Beta-Thalassemia (SJ-20-0030)
- Inhibition of eIF4A to improve T cell efficacy (SJ-22-0012)
- Interleukin-35 (IL-35) (SJ-06-0016)
- MAGE-A11 inhibitor for cancer (SJ-20-0033)
- MRT67307 treatments for enhancing NK cells (SJ-21-0020)
- Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
- Method to Activate Fetal Hemoglobin Expression (SJ-20-0020)
- Minimized Liver Specific Promoter to Improve Gene Therapy Vectors (SJ-04-0024)
- Modulating Regulatory T Cells By Targeting Foxp3 Enhancers (SJ-22-0010)
- Myd88 and CD40 costimulatory domains for chimeric antigen receptors (SJ-18-0021)
- Neuropiln 1 (Nrp1) modulation for immune system control (SJ-13-0012)
- Predicting T-cell development stage (and therapy success) (SJ-19-0033)
- Primer Panel for T cell receptor amplification (SJ-21-0039)
- Primer generation of T-Cell Receptor (TCR) sequences for immune response (SJ-19-0017)
- Promoter Modification to Reduce AAV Contamination (SJ-19-0003, SJ-23-0028)
- Protease Serine 21 (PRSS21) targeted immunotherapies (SJ-18-0043)
- REGNASE-1 gene knockout or BATF overexpression for improving T-cells (SJ-19-0027, SJ-20-0007)
- RIPK3 fusion protein for cancer and autoimmunity (SJ-12-0036)
- Rapid cloning of T cell receptors (SJ-16-0001)
- Regulating p53 translation and function (SJ-05-0002)
- SJ293TS cell line (SJ-19-0054)
- SJ293TS-DPB Cells for Lentiviral Vector Production (SJ-24-0024)
- Safety test for gene therapy vectors (SJ-15-0027)
- Selecting and modifying CD7 Cells (SJ-20-0012)
- Signatures associated with highly functional CAR T cells (SJ-22-0008)
- T-cell Aging Biomarker (SJ-23-0009)
- TNC and COL11A1 CARs (SJ-21-0009)
- Ulk1-/- Ulk2 flox/- hypomorph mice and cell lines (SJ-19-0004)
- Universal Chimeric Receptor for T-Cell Therapy (SJ-13-0031)
- Universal Synapse Enhancing Domain (PDZbm) (SJ-22-0011)
- VIPR1 modulators for improving auditory capabilities (SJ-22-0023)
- Zip Cytokine Receptor CARs (SJ-22-0002, SJ-23-0024)
- cBAF Inhibitors for Improving T Cell Immunotherapy (SJ-22-0015)
- miRNAs for treating cerebral ventricle enlargement in schizophrenia patients (SJ-19-0039)
- p53 inhibitory oligonucloeotides (SJ-09-0015)
For more information
Contact the Office of Technology Licensing:
Phone: (901) 595-2342
Fax: (901) 595-3148